143 related articles for article (PubMed ID: 26762561)
21. The phenotype of EZH2 haploinsufficiency-1.2-Mb deletion at 7q36.1 in a child with tall stature and intellectual disability.
Suri T; Dixit A
Am J Med Genet A; 2017 Oct; 173(10):2731-2735. PubMed ID: 28696078
[TBL] [Abstract][Full Text] [Related]
22. Acute lymphoblastic leukemia in Weaver syndrome.
Basel-Vanagaite L
Am J Med Genet A; 2010 Feb; 152A(2):383-6. PubMed ID: 20101679
[TBL] [Abstract][Full Text] [Related]
23. Histone code, human growth and cancer.
Crea F
Oncotarget; 2012 Jan; 3(1):1-2. PubMed ID: 22287500
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance of EZH2 in Acute Myeloid Leukemia.
Jiao W; Liu Y; Bao Y
Comput Intell Neurosci; 2022; 2022():8741989. PubMed ID: 36052036
[TBL] [Abstract][Full Text] [Related]
25. Novel findings in a patient with Weaver or a Weaver-like syndrome.
Scarano G; Della Monica M; Lonardo F; Neri G
Am J Med Genet; 1996 May; 63(2):378-81. PubMed ID: 8725789
[TBL] [Abstract][Full Text] [Related]
26. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes.
Douglas J; Hanks S; Temple IK; Davies S; Murray A; Upadhyaya M; Tomkins S; Hughes HE; Cole TR; Rahman N
Am J Hum Genet; 2003 Jan; 72(1):132-43. PubMed ID: 12464997
[TBL] [Abstract][Full Text] [Related]
27. Aberrant Expression of
de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
[TBL] [Abstract][Full Text] [Related]
28. Overgrowth syndromes.
Neylon OM; Werther GA; Sabin MA
Curr Opin Pediatr; 2012 Aug; 24(4):505-11. PubMed ID: 22705997
[TBL] [Abstract][Full Text] [Related]
29. A newborn diagnosed with van Maldergem syndrome.
Ulubas Isik D; Unal S; Erol S; Arslan Z; Bas AY; Demirel N
Clin Dysmorphol; 2018 Apr; 27(2):63-65. PubMed ID: 29505454
[No Abstract] [Full Text] [Related]
30. Two acute myeloblastic leukemia cases concomitant with hemophagocytic lymphohistiocytosis and review of the literature.
Akyay A; Celkan T; Iskender G; Tükün A; Ogan C; Olcay L
Ann Clin Lab Sci; 2013; 43(1):85-90. PubMed ID: 23462611
[TBL] [Abstract][Full Text] [Related]
31. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Basheer F; Giotopoulos G; Meduri E; Yun H; Mazan M; Sasca D; Gallipoli P; Marando L; Gozdecka M; Asby R; Sheppard O; Dudek M; Bullinger L; Döhner H; Dillon R; Freeman S; Ottmann O; Burnett A; Russell N; Papaemmanuil E; Hills R; Campbell P; Vassiliou GS; Huntly BJP
J Exp Med; 2019 Apr; 216(4):966-981. PubMed ID: 30890554
[TBL] [Abstract][Full Text] [Related]
32. [Clinical Analysis of Acute Myeloid Leukemia Patients with Hemophagocytic Syndrome].
Wang YP; Wu SX; Zhang XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):92-98. PubMed ID: 35123609
[TBL] [Abstract][Full Text] [Related]
33. EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway.
Zhang H; Gu H; Li L; Ren Y; Zhang L
Tumour Biol; 2016 May; 37(5):5919-23. PubMed ID: 26592252
[TBL] [Abstract][Full Text] [Related]
34. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
[TBL] [Abstract][Full Text] [Related]
35. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
Li Q; Song W; Wang J
Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
[TBL] [Abstract][Full Text] [Related]
36. Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia.
Rivera OD; Mallory MJ; Quesnel-Vallières M; Chatrikhi R; Schultz DC; Carroll M; Barash Y; Cherry S; Lynch KW
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876749
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of NSD1 mutations in Sotos and Weaver syndromes.
Rio M; Clech L; Amiel J; Faivre L; Lyonnet S; Le Merrer M; Odent S; Lacombe D; Edery P; Brauner R; Raoul O; Gosset P; Prieur M; Vekemans M; Munnich A; Colleaux L; Cormier-Daire V
J Med Genet; 2003 Jun; 40(6):436-40. PubMed ID: 12807965
[TBL] [Abstract][Full Text] [Related]
38. Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
Saygin C; Hirsch C; Przychodzen B; Sekeres MA; Hamilton BK; Kalaycio M; Carraway HE; Gerds AT; Mukherjee S; Nazha A; Sobecks R; Goebel C; Abounader D; Maciejewski JP; Advani AS
Blood Cancer J; 2018 Jan; 8(1):4. PubMed ID: 29321554
[TBL] [Abstract][Full Text] [Related]
39. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
40. MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia.
Xiang Z; Abdallah AO; Govindarajan R; Mehta P; Emanuel PD; Papenhausen P; Schichman SA
Cancer Genet; 2015 Mar; 208(3):96-100. PubMed ID: 25800664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
